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Kinase enzymes play an important role in many biological processes and their malfunction in 
the body can lead to diseases, such as cancer and muscular dystrophy. Covalent kinase 
inhibitors are a relatively new and exciting field of research in drug discovery due to 
advantages in selectivity, provided toxicity from off-targeting effects can be controlled. Our 
industrial partner (KeyOrganics) required a small but diverse fragment library of such 
molecules for fragment-based drug discovery (FBDD) applications. In this report, we present 
a versatile route to a wide variety of cyanoacrylamides for this purpose that is largely 
underrepresented in the literature; cyanoacrylamides have been shown to be reversible 
inhibitors and were of particular interest as a result. 
To achieve this, cyano-acrylic acids were synthesised as precursors to the amide coupling 
step, and the ability to vary both the acids and the amines of this reaction sequence created a 
flexible method. 17 Fragments were made from 3 precursor acids using this approach, and the 
process was adapted and optimised over time using different coupling reagents and methods.  
Due to the application of these fragments, testing was conducted by reacting the molecules 
with glutathione (in place of the reactive thiol residue present in kinase enzymes) to get 
relative comparisons of their binding affinities. This was monitored via 1H NMR, where the 
variation in size of the relevant integral on the inhibitor could be linked to reaction with 
glutathione. Most of the fragments tested binded to the thiol residue but in different extents, 
and the behaviour of the integral sizes over time was indicative of reversible inhibitors.  
The binding affinities were compared by fitting the data to first order kinetics to yield a rate 
constant for the interaction. While the quality of fit was not good enough to give any 
quantitative data, it did allow for relative comparisons of inhibitors, and a trend could be seen 
in their performance based on estimated steric/inductive effects. However, the solvent used 
for this test likely interfered with the equilibrium (as seen in one case) by providing an 
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Fragment based drug discovery relies on a diverse library of molecules to screen1, and the 
major objective of this work was to produce and evaluate a range of new fragment molecules 
in the rising field of covalent kinase inhibitors. This new class of kinase inhibitors have seen 
an increased interest in recent years and can present notable advantages to their non-covalent 
counterparts. It is thus important to have an appropriate fragment library of these molecules 
to provide a large array of species to test.  
1.1 The rise of fragment-based drug discovery  
 
High throughput screening (HTS) has long-established problems with high attrition rates1, 
meaning the majority of hits found (i.e. potent compounds against a target) are discarded 
soon in the development process. In an attempt to address this, FBDD identifies low-
molecular-weight ligands (in the region of 300 Da or less) that bind to the biologically 
important macromolecules related to the disease in question. The key difference between 
FBDD and HTS is that FBDD focuses more on the quality of fit of a fragment to a binding 
site on the protein target, whereas in HTS potency is the main driving force for selection of a 
hit compound2.  
The three-dimensional experimental binding interaction can be investigated via NMR or X-
ray Crystallography, and this extra information is used to better optimise fragments into lead 
compounds3. Although initial fragments have poor potency as a result of their small size, they 
typically form high quality interactions and can be readily converted into leads using this 
method. In addition, Proficient fragments can also be combined to yield a more potent 
combination. An illustration of the conversion of a fragment to lead compound is shown on 
















Figure 1 illustrates how a fragment can be moulded into a lead compound, and how 
information about the binding mode is used to understand how best to fit an inhibitor to the 
target (i.e. the blank spaces in the diagram give an indication of how to alter the fragment). 
Optimising in this way improves potency, giving a stronger lead compound. While the more 
traditional HTS approach will tend to find a lead compound faster, fragment-based 
approaches are becoming more popular due to their more scientific nature and lower attrition 
rates. Both methods are considered viable as a result but FBDD allows progress to be made 
with only a small library of compounds, making it more accessible in that regard.    
Since the first report of the fragment-based method in 1996, two clinically approved drugs 
have been developed and at least 30 FBDD-derived compounds are in various stages of 
clinical development4. Notable challenges for FBDD include the need for specialised 
techniques for screening as the fragments will have weaker binding affinities than the 
molecules tested in HTS.  
FBDD is now frequently adopted in the pharma industry but (due to its method) requires 
varied fragment libraries for each drug discovery case in order to be effective. Hence the need 
for this project and its collaboration with an industrial partner.  
 
 
Figure 1: Illustration of how fragments can be optimised for a specific target1 
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1.2 Kinase and an overview of current covalent inhibitors 
 
To understand this particular class of fragments, it is 
important to first understand Kinase enzymes and the details 
of their inhibitors. Kinase inhibitors block the action of 
Kinase enzymes, which moderate the process of 
phosphorylation5 whereby a phosphate group is added to a 
substrate (specifically a protein in this case) using Adenosine 
triphosphate (ATP) as a phosphate donor (see Figure 2). The 
process can also be reversed via the action of phosphatases.  
Phosphorylation changes the activity of a protein in various 
ways, and leads to the activation of signal-transduction 
pathways which are crucial in many biological processes6. Protein 
Kinases thus play an important role in intracellular signalling pathways, and these regulate 
cell growth, differentiation, development, functions and death.  
As a result, any disruption of the phosphorylation process will alter cell function and can 
result in disease. There are about 550 human protein kinases7, so the need for specificity in 
any inhibitor is paramount. Inhibition (and thus regulation) of a 
deregulated protein kinase can be desirable in combatting ailments 
such as Cancer, Alzheimer’s disease and Muscular Dystrophy. 
For example, Chronic Myelogenous Leukaemia (CML), is caused 
by excess activity of the Abelson tyrosine kinase8. Imatinib (see 
Figure 3) is a molecule designed to bind to the active site of this 
particular kinase and inhibit its ability to phosphorylate targets, 
thus regulating it.                                                      
Kinase inhibitors are classified into types depending on where/how 
they bind to their targets9: Type 1 inhibitors bind to the active 
kinase conformation while the inactive form is targeted by the type 
2 class. Both type 1 and 2 inhibitors occupy the adenine binding pocket of the kinase, 









Figure 2: Protein Kinase 
phosphorylation process5 
Figure 3: Imatinib molecule 
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Type 3 inhibitors bind next to the ATP-binding pocket, and type 4 variants do not bind to 
either of the ATP or peptide binding sites; these two are both allosteric in nature, meaning 
they bind to an effector molecule at a site other than the enzyme’s active site. Type 5 
inhibitors are bivalent, meaning they bind to two different regions of the protein kinase 
domain, and type 6 inhibitors bind through covalent means.                                                                                                                                                                                                       
The majority of kinase inhibitors have been non-covalent in their binding up until now, and 
this is largely due to toxicity concerns of off-targeting effects10 (i.e. a covalent bond is far 
more permanent than, for example, a hydrogen bond). However, recent research has shown 
that with a carefully designed inhibitor for the target site, covalent drugs can be viable. They 
can also gain added selectivity11 from the covalent binding mode as the inhibitor can be 
assembled with a specific covalent interaction in mind; This measured approach goes hand-
in-hand with the nature of FBDD.  
Over the past few years, the FDA have approved 4 covalent kinase inhibitors, and this has 
resulted in a renewed interest in their research. One of these (see Figure 4), Afatinib12, is to 







Like Imatinib, it is a type of tyrosine kinase inhibitor, and blocks the proteins sending signals 
to the cancer to grow. Blocking the signals causes the cells to die, which may help stop or 
















Figure 4: Afatinib molecule 
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To act as a covalent kinase inhibitor, drug molecules require a reaction moiety known as a 
warhead10, which is key to finding the balance between toxicity and efficacy. It is the 
warhead which helps to improve the binding affinity and selectivity of the covalent 
interaction with the reactive residue of the kinase. Covalent interaction-related residues in 
kinases can be cysteines, lysines and aspartic acids among others, although most often they 
are non-catalytic cysteines near the ATP-binding site.                                                                                                                                                                       
A paper on the recent progress of the field10 investigated covalent small-molecule kinase 
inhibitors (CSKI’s) from recent papers and databases, ranking the most common warheads 
being utilised (see Figure 5 on next page). The most popular choice by far were the 
acrylamides and their related derivatives, which interact via a 1,4-addition of the cysteine 
thiol to the conjugated carbonyl (Afatinib has this warhead for instance). Many of the other 
warheads form covalent interactions in a similar way, such as enones (ranked 3rd in Figure 5) 
and cyanoacrylamides (4th).  
 
Figure 5 shows a large variety of functional groups being explored for covalent kinase 
inhibition and the distribution on the right-hand side of Figure 5 shows the variety of sections 
of kinase that have been targeted with these warheads. Unlike the other warheads, the 
cyanoacrylamides were noted to have been used as reversible inhibitors of Kinase, making 
them particularly interesting to this project.  
Figure 5: Figure ranking the popularity of different warhead types for all covalent small-molecule kinase 
inhibitors from recently published review papers and databases10 
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Reversibility allows for more control over the reactivity with the target10, which may help in 
treating different ailments that require less permanent modifications to enzymes. Also, all 
cyanoacrylamides covered in the study target cysteines in the P-loop region, in contrast to the 
behaviour of the other popular inhibitors which target a range of cysteine residues.   
1.3 Cyanoacrylamides as reversible covalent inhibitors 
                                                                                                                                                          
Further investigation into this reversible nature found a study in which13 simple thiols (akin 
to the cysteine residues on a protein kinase) were seen to be reacting immediately with 2-
cyanoacrylates, but products of the interaction could not be isolated. It was shown that this 
only occurred when both the ester and nitrile groups were together on the molecule, as the 
interaction with the lone esters and nitriles did not result in this observation. 
By using 1H NMR and dilution experiments (see Figure 6), it was confirmed that the adduct 
thioether did form, and that the reaction was rapidly reversible with a tuneable equilibrium. 
The first spectrum in Figure 6 shows the lone cyanoacrylate, the middle spectrum shows it 
treated with β-mercaptoethanol (βME) in DMSO-d6:PBS-d (3:1) giving a mixture which 
favoured the adduct 15:85, and the bottom spectrum shows a ten-fold dilution which shifts 
the equilibrium towards the left (45:55). The red and blue asterisks indicate peaks that were 















It was this uncommon property and the lack of exposure for these molecules compared to 
regular acrylamides that resulted in cyanoacrylamides becoming the focal point of this 
project. More specifically, the aim was set to make at least 15 fragments with at least 20 mg 
of each to allow for appropriate testing in pharmaceutical applications.                                                                                           
A previous paper on cyanoacrylamide synthesis14 for use as kinase inhibitors involved an 
array of aldehyde fragments which were combined with cyanoacetamide in a condensation 
reaction (see Figure 7). These fragments were screened against three human kinases, giving 
notable differences in potency. The method yields a decent variety of fragments, but the 
majority of these are based off of similar aromatic rings and the amine portion of the 









Thus, creation of a set of fragments using a similarly formulaic approach, but with a larger 
variation in the molecules was seen as an effective route for the project aims. This would 
allow room for further understanding of what makes a fragment particularly effective in 
binding to kinase, while deviating from the papers approach of a condensation reaction and 
variation of the aldehyde. The chosen method was an amide coupling, which was quite 




Figure 7: Set of cyanoacrylamide fragments made in a previous study14 
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Similar to the acrylamides, the cyano-equivalents are electrophilic and would likely interact 
with the reactive thiol group of cysteine residues on the kinase in a type of Michael addition 
(see Figure 8). The position of the nitrile group increases the susceptibility of the β-carbon to 
nucleophilic attack as it is now more electron deficient, improving binding affinity13. Its 






In order to compare cyanoacrylamides made in this project, this interaction would need to be 
mimicked and any changes observed/measured. A similar test was used in a recent paper16 
whereby covalent inhibitors were reacted with an excess of Glutathione (Figure 9), which is 





The interaction was monitored via LC-UV-MS, allowing the researchers to produce a 
pseudo-first order rate constant and compare their molecules quantitatively. Due to the 
applications of the molecules that would be produced in this project, it became a secondary 
aim to test some of the fragments made in a similar fashion.                                                                                                                         
The performance of similar inhibitors tested in another recent paper was found to be closely 
related to the electron-withdrawing nature of substituent groups and steric effects. We would 
thus expect a similar impact on the molecules produced in this project. Later on, a more crude 
method was implemented using 1H NMR which gave good relative data, and was also able to 
highlight the reversible behaviour of the inhibitors.  
Figure 9: Glutathione molecule 
























2 Results and Discussion 
 
Initial work centred on finding methods of making cyanoacrylamides that could be repeated 
in a formulaic fashion, such as the one mentioned in the introduction. This led to the 





The process, using 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) in a standard 
amide coupling procedure, was seen as a potential route to an array of cyanoacrylamides 
through variation of both starting reagents. The cyano-acrylic acid (and variants of it) would 
also make valuable precursors (to the industry) for these types of molecules if the versatility 
of the route could be proven. The process used in the referenced paper was part of a larger 
scheme to synthesise a different molecule, so its capabilities with producing different 
cyanoacrylamides was not explored. Amide couplings in this way to form cyanoacrylamides 
have not been covered very much overall, and thus it was thought to be valuable to 
investigate this approach further. 
2.1 Precursor molecule synthesis 
Synthesis of a selection of cyano-acrylic acid molecules to explore this route in depth became 







Figure 10: Potential method for varied cyanoacrylamide synthesis17 













The molecules were chosen to provide varying degrees of steric influence and inductive 
effects. Other options could have been the isopropyl or substituted benzyl precursors, but 
these 3 were chosen on account of simplicity and ease of availability of the starting materials 
to make them from. Preparation of the cyclopropyl precursor (1) is documented in literature 
as well as some aromatic versions, but the cyclohexyl variant (2) had not been seen in the 
literature. The synthetic methods found typically used piperidine as a catalyst, and the chosen 




This was attempted for the compounds in Figure 11 with mixed results. Synthesis of the 
cyclohexyl and cyclopropyl variants worked well and gave the best yields; they were also 
easiest to purify. However, the benzyl precursor was more difficult to make as purely, and the 
reaction gave poorer yields. This could have been due to added steric bulk of the aromatic 
group which may hinder the reaction progressing. The yields of each reaction can be seen 
below: 
Table 1: Yields of cyanoacrylamide precursor syntheses 
Synthesis of a tert-butyl precursor (see Figure 13) was also attempted, but the reaction 
appeared to have trouble going to completion. The 1H NMR showed a peak that did not 
belong to the desired product (see Figure 14 on next page), and it was 
thought that this was one of the starting materials. As there were some 
difficulties with the benzyl precursor as well, it makes sense that the 
even bulkier tert-butyl form would pose problems.  




Figure 12: Synthetic route for the compounds in Figure 11 




















The Figure above shows the 1H NMR of the sample for the tert-butyl reaction, annotated with 
the identity of each peak. The peak in question at 3.86 is not supposed to be in the final 
structure. Mass spectrometry (MS) of the sample confirmed that some of the product had 
been made, but it also confirmed the presence of the starting 2-cyanoacetic acid and the 
theory that the reaction had not gone to completion. Attempts were made to do the reaction 
with an excess of the aldehyde (as opposed to a 1:1 ratio) and for a longer period of time, but 
these gave the same outcome.  
Finally, the procedure followed stated that the crude product precipitates out of the reaction 
mixture when cooled to zero degrees and was removed by filtration. This was not observed in 
any of the syntheses in this project and the solvent was removed via rotary evaporator to get 

















Figure 14: NMR of tert-butyl precursor, showing desired peaks as well as a substantial unexplained peak, likely to be 














































2.2 Cyanoacrylamide synthesis and evolution of the method 
The three successful precursor molecules were then used in amide couplings (using the 
conditions in the paper of Figure 1017) with a variety of amines (mostly supplied by 
KeyOrganics). One such reaction was successfully attempted with the benzyl precursor: 
 
Synthesis of cyanoacrylamides 4 and 5 were done with N,N'-Dicyclohexylcarbodiimide 
(DCC) instead of EDC due to availability issues, but the two work very similarly. DCC was 
later replaced by EDC due it being easier to remove from the reaction mixture. The reaction 
of the benzyl precursor and benzylamine (Figure 15) was successful, giving an adequate 
amount of material for the original aims of the project. More reactions were attempted with 
the other precursors due to their better yields and purities, and those reactions carried out with 











Figure 16:Attempted cyanoacrylamide syntheses from the cyclopropyl precursor and their results 









DCC, HOBt.H2O, DIPEA, DCM/DMF (10:1 v/v), 





A wider selection of amines was used here, giving mixed results. The benzylamine coupling 
(5) worked as well as it did for the benzyl precursor, giving the same yield and a similar 
amount of material. The other two successful reactions (6 and 7) gave better yields, but the 
majority of couplings in Figure 16 failed to yield useable products.  
Couplings with cyclohexylamine, 1-methylpiperazine and pyridine-3-ylmethanamine (2nd 
row) seemed to work from the NMR data but purification (by flash chromatography) was an 
issue. Final products were either very impure or failed to leave the column. The last reaction 
with 2-chloroaniline had problems with conversion, with just the starting aniline coming out 
after an attempt at purification. This was likely due to the reduced nucleophilicity of the 
amine (which needs to attack the carbonyl on the acid to react), on account of the 
electronegative chlorine and mesomeric electron-withdrawing effect of the aromatic ring. The 
reaction was left for longer to try and accommodate for this, but it was still unsuccessful.  







Again, these are in similar yields and amounts to the reactions with the other precursors. 
Overall, the process worked for 6 of the 10 coupling reactions tried, giving a decent array of 
initial fragments. Problems arose in poor yields (although they gave adequate amounts for our 
initial aims) and difficulties with weakly nucleophilic amines, but the main issue with the 
method was the need to use 1-hydroxybenzotriazole (HOBt, see Figure 18) in the reaction. 
This reagent is explosive when dry, and the restricted material became unavailable halfway 
through the project.  
 
 
Figure 17: Attempted cyanoacrylamide syntheses from the cyclohexyl precursor and their results 




















The need for this reagent stems from the need to suppress racemization in carbodiimide-
mediated coupling reactions19. This is key in this project particularly as different enantiomers 
can have different binding affinities and activity levels in the body20. The lack of availability 
for this reagent and the problems found with the method led to the use of a new coupling 
agent. 
In future, HOBt should probably be substituted directly for a less problematic option such as 
OxymaPure, but for this project it was chosen to use HATU (below), which combines a 










The same conditions were used for the HATU couplings as before, with the lack of HOBt 
being the only other difference to the previous method. The results of these reactions for the 




Figure 19: HATU molecule, 
showing HOAt and HBTU 
components 






































The two unsuccessful reactions failed in the purification stage, and a different column solvent 
was likely needed to get them out successfully. It is worth noting that the morpholino-amine 
(right side of Figure 20) worked with the cyclohexyl precursor but not with the benzyl 
equivalent. However, the cyclohexyl reaction was likely aided by its reduced steric bulk and 
had a different Rf value. The one reaction that was successful (compound 10) gave the best 











The results with HATU were generally strong, with good yields overall and mostly successful 
reactions. Notably, the reaction with cyclohexylamine (11) worked far better than the failed 
EDC attempt (in Figure 16), although it was still not entirely pure. This was the only EDC 
reaction that was repeated with HATU, so a full direct comparison between the two methods 
was not possible.  
It was also interesting that the 4-chloroaniline reaction was successful considering that the 2-
chloro counterpart was not. This may be due to the use of HATU, or the amine may have 
been more nucleophilic as the electron withdrawing chlorine atom is positioned further from 
the amine; this could have helped the reaction progress further. Finally, reactions attempted 
with the cyclohexyl precursor are shown on the next page (see Figure 22). 
 
 










































Similarly to the other HATU results, these reactions were largely successful, with most 
giving better yields on average compared to the EDC method. The unsuccessful 2-
chloroaniline (Bottom right) reaction from the cyclopropyl set was tried here but failed to 
give any usable product again. Mass spectrometry of these samples did show that some of the 
cyanoacrylamide had formed, but the lack of conversion was clear to see on the NMR 
spectra. It is also interesting to note that, while the trifluoro methyl aniline (16) worked in this 
coupling and gave a strong yield, the same amine without the methyl group was unsuccessful 
(bottom row, middle in Figure 22). The crude NMR’s indicated the reaction had not gone to 
completion very well and the mixture was swamped with what appeared to be HATU. 
The amine is not very nucleophilic for similar reasons as the 2-chloroaniline, and it may be 
that the effect of the methyl group in molecule 16 was able to push the reaction far enough to 
completion, although the product of that reaction itself was not entirely pure.  






















































And the final unsuccessful reaction (bottom left) failed in the purification stage, likely 
needing another column solvent such as DCM:Methanol. Further improvements to the 
method include the introduction of a workup which was not present in the original literature 
procedure. This came largely as a result of poor product purity, with large amounts of HATU 
also being found in some final products. Finding the coupling agent in the final product was a 
much more notable issue with HATU compared to the carbodiimide reactions.     
2.3 Investigation into Stereochemistry    
 
The stereochemistry of the molecules produced in this project was debatable, as the nitrile 




Typically, the NMR coupling constants between the two protons on the alkene bond would 
provide an answer, as they differ depending on the conformation of the double bond21. 
However in this case, there was no such pair of protons where this could be seen due to the 
presence of the nitrile group on the alkene.  
Structural probing methods such as X-ray crystallography would have been able to 
distinguish between the two, but these were not available so instead an attempt was made 
through NOESY (Nuclear Overhauser Effect Spectroscopy)22. This is a 2-D NMR method 
which highlights through-space interactions between protons in close vicinity. When a proton 
is saturated or inverted, nearby protons may exhibit an intensity increase, dubbed the Nuclear 
Overhauser Effect (NOE). This effect is unique among other NMR techniques in that it 
depends solely on the spatial proximity between protons, not via through-bond J couplings. 
To show a signal on the NOESY spectrum, a molecule needs to be able to align the relevant 
protons in close vicinity. The Figure on the next page shows how the two possible 
conformations can orientate themselves to give a NOE (using the cyclopropyl group as an 
example). It shows that an amide (or hydroxy)-alkene NOE correlation could only be seen if 
the nitrile group was cis to the double bond (left-hand side of Figure 24).  



















In the other configuration (right side), the amide proton cannot angle itself to be in close 
vicinity with the alkene proton and would not show NOE correlation. NOESY spectra were 
ran on the 3 precursor acids and 3 of the cyanoacrylamides which showed clear alkene/amide 
1H NMR peaks. If the spectra showed a 2-D cross peak, the molecule would have to be in the 
cis-nitrile format. The data from these spectra was not great overall, as 5 of the 6 samples did 
not show clear correlation between the protons in question, and the samples were not 
completely clean which may have interfered with the data.  
However, one of the cyanoacrylamides (fragment 15) did show such a correlation (see 
below), albeit a weak one, and the lack of correlation in the other samples does not 
necessarily mean their protons are not in close vicinity, due to the dynamic nature of the 
NOE23. As a result, it can be confirmed that this molecule, and likely the other fragments 
from the cyclopropyl precursor, are of the conformation shown in this report.  
Figure 25: NOESY spectrum for fragment 15, showing a weak NOE signal (circled) between the alkene proton at 7.1 
ppm and N-H proton at 10.2 ppm. N-H proton not shown on spectrum here but can be seen in regular 1H NMR 

















The other molecules tested using this method cannot be assigned stereochemistry in such a 
conclusive way, but this result does allow for the assumption that they would adopt the same 
conformation. The surrounding literature also supports these results.  
The molecules in this report are all pictured with the nitrile group cis to the olefin as this is 
how they were shown in surrounding literature reviewed. Further investigation into these 
sources yielded more information on the stereochemistry of these types of molecules. Firstly, 
a source covering the synthesis of compound 124 also studied a version of the molecule 
without the nitrile group (see below). The alkene bond in this molecule was confirmed to be 
trans with respect to the carboxylic acid group via 1H NMR coupling constant of the two 
protons on the alkene. 
 
This supports the claim from the NOESY experimental data. Furthermore, the source from 
which Figure 10 (the amide coupling method) was acquired uses alpha-Cyano-4-
hydroxycinnamic acid (CHCA), a well-known molecule which has been studied far more 
than those made and used in this project. The results from X-ray crystallography analysis25 
on CHCA show the carboxylic acid group again adopting a trans configuration (see Figure 








CHCA is very (structurally) similar to the benzyl precursor used in this project, so the 
molecules based on this precursor can likely be assumed to adopt the same conformation. 
This source also supports the NOESY data, and as a result the molecules in this project have 
all been drawn with this conformation.  
Figure 26: Version of compound 1 without nitrile group, proven to be in the trans configuration24 





2.4 Glutathione testing 
 
In total, 17 successful cyanoacrylamides were produced, out of 28 total coupling reactions 
during this project. As FBDD focusses on a strong fit to its target as opposed to biological 
potency, it was considered important to test a subset of this small fragment library in terms of 
binding affinity in a pseudo-real case. A test was devised using 1H NMR as mentioned before 
to follow the interaction of some of the inhibitors with Glutathione and get preliminary data, 
as well as to deduce the contributing factors to a strong binding mode in this case. The paper 
that inspired this test used LC-MS, but this was not selected for this test due to unavailability 
of this instrument and the simplicity/ease of peak identification of NMR. 
In a similar way to the interaction of 2-cyanoacrylates with β-ME (see Figure 6), if the 
reactive thiol in glutathione interacted with an inhibitor, the environment around β-hydrogen 
would change (from alkene to alkane). As a result, there would be a measurable drop in the 
alkene proton peak which would be proportional to a reduction in inhibitor concentration 








If the process reaches an equilibrium, it should be possible to see this happening in NMR as 
the integral height would begin to plateau or fluctuate. This would be a good indication of the 
reversible behaviour of cyanoacrylamides and, depending on the depletion of the integral, 
would also allow for relative comparison of the inhibitors for their binding affinities in the 
form of rate constants for these interactions. 
Detect by depletion of original alkene proton 
peak here in H NMR. 























Difficulties arose with this method initially in terms of solubility however. The paper being 
followed described an excess of Glutathione reacted with inhibitors in water, but the 
fragments in this project are not soluble in water. The reactions therefore had to be ran in 
deuterated DMSO which glutathione is only sparingly soluble in. As an initial test, a subset 
of 3 fragment molecules were reacted in excess with glutathione to see if there was any effect 
in the NMR data. This ratio of reactants meant that there would be less glutathione to 
dissolve to get the interaction started.  
As mentioned in the introduction, the interaction should depend largely on the electrophilicity 
of the inhibitor (i.e. its susceptibility to nucleophilic attack from the thiol residue), so the 
electron withdrawing nature of the amine portion should have a major impact on binding 





Note that only fragments from one precursor molecule (cyclopropyl) were selected in order to 
compare the effect of the amine only. Of these 3, only fragment 12 was noticeably affected 
by the interaction, and is shown in Figure 30 on the next page. This result is in line with 
previous expectations as the amine portion is both more electron-withdrawing than its chloro-
variant (15) and far less bulky compared to fragment 6.  
The graph shows how the size of the alkene proton on fragment 12 varied over hourly 
intervals after being mixed with Glutathione. The alkene proton was set to 1 in the pure 
inhibitor NMR and was then measured compared to a known NMR peak in the inhibitor that 

























The proton integral dropped noticeably from its initial level, peaking at 21% loss. The 
behaviour of the graph over time is also important; it plateaued almost immediately, which is 
a sign of an equilibrium being found. This may however be due to the glutathione being the 
limiting reagent in this test, and the inhibitor may have simply reacted with all the glutathione 
present in the sample. An NMR taken 24 hours after the interaction began gave a proton 
integral of 0.79, so the effect was sustained. 
Fragments 6 and 15 were monitored in the same way for a similar amount of time (as were 
future tests) and showed no noticeable difference. The reason for monitoring the interaction 
for such a short length of time is because this was purely preliminary data used to probe the 
interaction (if any) taking place.  
The data can (largely for ease of comparison as opposed to accuracy) be best fitted to first 
order kinetics (like in the paper this method is based upon) via a natural log vs time graph. 
The negative gradient of the trendline gave a rate constant for the interaction, 0.057 hr-1, left 
in units of hours for convenience sake. This value is solely for relative comparison, and the 
R² value (0.4597) indicates the level of correlation between the data and the trendline it has 
been fitted to. With a value of 1 representing perfect correlation and 0 representing no 
relation between the data points, this data does not correlate well and thus cannot be 
considered quantitative. Although, in most of the later experiments, the correlation was much 






















Proton integral vs Time in reaction with Glutathione
Figure 30: Graph showing variation of inhibitor proton integral upon reaction with Glutathione over time 
30 
 
From this initial data, it was concluded that it is viable to garner relative data using this 
method and that further preliminary testing on more fragments would be of use to the project. 
To better probe the interaction, a 1:1 ratio of inhibitor:glutathione was used in future tests. If 
the inhibitor was reacting with all glutathione present, the NMR would show complete 
depletion of the proton integral to zero and this could be confirmed. 6 fragments were tested 
using the 1:1 conditions, giving mixed results. The table on the next page (Figure 31) details 
the rate constants for these experiments (kGSH), along with the R2 value for the natural log vs 





Figure 31: Table showing rate constants and R squared values for the 1:1 interaction between various fragments and 
Glutathione 
 
The higher the rate constant, the more favourable the interaction and thus the better relative 
binding affinity of the fragment to the glutathione. Two of the fragments didn’t have an 
interaction, one of these being a repeat fragment from Figure 29 (fragment 6) and the other 
being fragment 7. 







































































The trifluoro group in fragment 7 is very strongly electron withdrawing but was not favoured 
in this interaction, presumably due to the steric hinderance of such a nearby aromatic ring, 
and a somewhat bulky trifluoro group. This is further evidenced by fragment 16, where the 
added methyl group seemed to give the space needed to accommodate an interaction.                                                                                 
Fragment 11 was structurally less imposing compared to the other fragments tested, and this 
seemed allow it to inhibit the glutathione, albeit to a small extent. More favourable 
interactions came from the other two entries in the table, with fragment 8 having a 
morpholino group with two electronegative atoms which were separated from the amide by 
two methyl groups. This combination provided steric and inductive favourability towards an 
interaction, so it made sense that this yielded the highest rate constant. Fragment 14 has a 
similar make-up with electronegative atoms and bulky groups at a good distance from the 
amide, although to a lesser extent, giving it the second-highest rate constant. Overall, the 
best-performing fragments having some separation between their bulkiest groups and the 
amide was a noticeable trend here. Note also that the final 3 entries in this table showed much 
improved R2 values. The data shows an interesting variety of rate constants, and importantly 
the plateau behaviour exhibited in the first test was mostly maintained here, which implies 
partial, reversible inhibition of the glutathione and an equilibrium being reached.  
The data for the first entry in Figure 31 was particularly interesting, as it seemed to show a 
back-and-forth between the binded and unbinded forms of the glutathione adduct. The 



















Proton integral vs Time in reaction with Glutathione (1:1)






This behaviour was very different from the other fragment interactions in which the integral 
merely dropped and levelled off immediately. Each hour, the size of the integral changed 
noticeably, initially rising (it is unknown as to why) and then dropping to its minimum value 
of 0.79 (a 21% reduction on the starting value) before rising again to 0.90. An NMR taken 24 
hours after the interaction showed the integral had effectively returned to its original size 
(1.03).  
Naturally, the effects of Le Chatelier’s principle on equilibria were considered when trying to 
explain this behaviour. As conditions around the sample remained largely the same (i.e. 
temperature pressure etc), the loss of one of the reactants was thought to be the culprit, as this 
would cause the equilibrium to favour the reactants to account for this loss. It is unlikely that 
the inhibitor compound would degrade under these conditions or take part in any side 
reaction, but the thiol source (glutathione) could have been lost in another reaction due to its 
role in the body.  
Glutathione is an antioxidant present in cells in the body which helps to remove reactive 
oxidising species by undergoing a redox reaction in which it is oxidised26. The product is the 
dimer, glutathione disulfide (see Figure 33), and the process in turn causes reduction of these 
reactive species, protecting the cells from any damage they might cause. To give an example, 
sufferers of Cystic Fibrosis have a lower concentration of glutathione compared to others27.  
 
This dimerization also happens to the lone cysteine amino acid (which makes up the thiol-
section of glutathione) in the body to form disulphide bonds in proteins28. The sulfur atoms in 
this dimer form would be far less likely to interact with an inhibitor molecule. Thus, this 
would result in a loss of the reactive thiol in the inhibitor-test reaction mixture and a shift in 
the equilibrium (like that seen in Figure 32).  
 




































To have this interaction be possible, there would need to be an oxidative environment in the 
glutathione tests and the solvent (DMSO) provides that. A recent paper29 studied the 
interaction of l-cysteine with a slight excess of DMSO at room temperature for 24 hrs. Using 
infrared spectrometry, the reaction was monitored and substantial changes to the mixture 













The initial mixture (graph a in Figure 34) and much-changed sample after 2 hours (b) can be 
seen on the bottom side of the Figure, and b was later isolated and found to be l-cystine (c), 
the dimeric form of l-cysteine. As a result, it is likely that glutathione in the inhibitor tests 
was being lost to a similar oxidation, with the DMSO being reduced to dimethyl sulphide 











3 Conclusions and Further Work 
 
The work detailed in this report highlights the potential of this synthetic route to a diverse 
range of cyanoacrylamides. The initial aims of the project have been met using this approach, 
with more than 15 fragment molecules made and the majority of them in appropriate 
amounts.  
However, while in theory fragment synthesis using this method can work with all reactants, 
in practice it is clearly not a “one size fits all” process. Making the 17 cyanoacrylamides in 
this project has required variation in purification, method and coupling reagents, and each 
synthesis requires its own optimisation approach. As a result, not all syntheses worked, and 
the route faced problems in purification and conversion aspects at times. 
 Other synthesis options were also considered during this project (partly to counter these 
problems), such as the conversion of the precursor acids to acyl chlorides to give the carbonyl 
a more favourable leaving group with a lower pKa (see Figure 35):                                                                                                                                  
 
This would eliminate the need for coupling agents and the reagents they require and may also 
aid reactions with weakly-nucleophilic amines such as the 2-chloroaniline discussed earlier. 
The reason for not doing this conversion during the project was because of the requirement of 
an extra step in the scheme, as well as the fact that the aim of getting at least 15 fragment 
molecules took priority. This is a point to consider for future work as a result. In addition, 
looking into more precursor molecules such as the isopropyl variant (Figure 36) would also 
be worth doing to further show the potential of this synthetic plan: 
 













Figure 35:Alternative approach converting our precursor molecules into acyl chlorides 
 
 






The tests involving glutathione in this project were adequate for comparisons of relative 
binding affinities, and good comparisons were made for the fragment. However, a more 
quantitative investigation would be useful in future and the method could be modified for 
this. For instance, using an internal standard for the NMR would allow for direct conversion 
of integral size to concentration, and access to additional data such as equilibrium constants.  
Conditions in the body could be simulated with a pH buffer solution (pH 7.4) and heating of 
the sample to 37 degrees, while glutathione could be reacted in excess (like in the original 
paper) as this would likely be the case in the body. Following the interaction for longer would 
also help the quality of the data and allow for better understanding of equilibria but the 
method in this project was done out of convenience and the need to get relative data. The 
potential for this method can easily be seen however. 
In addition, DMSO should not be used in future tests due to the potential oxidative 
environment it provides which was thought to interfere with our testing. Finding a solvent 
that would dissolve both the fragments and glutathione while not interfering with the 
equilibrium would be challenging and take time. Hence this would be another point to 




4.1 General Experimental Practice 
Starting reagents were obtained from commercial suppliers and were used without further 
purification, except for the majority of amines used in cyanoacrylamide syntheses which 
were supplied by KeyOrganics, the industrial collaborator for this project. All water used in 
the reactions was deionised and organic extracts were dried over anhydrous sodium sulfate 
before solvent removal using a Büchi rotary evaporator.  'Petrol' refers to the fraction bp 40-
60°C, “DCM” refers to Dichloromethane and “EtOAc” refers to ethyl acetate. NMR spectra 
were retrieved at 298 K, at 400 MHz using a Bruker AV400 or AVIII 400 and were typically 
run in a solution of CD3OD (deuterated methanol) (or (CD3)2SO (deuterated DMSO) in some 
cases).  
NMR shifts are given in ppm downfield and the residual solvent peak (CD3OD δH 3.31, δC 
49.00, (CD3)2SO δH 2.50, δC 39.52) was used as an internal standard. All coupling constants 
are given in Hertz (Hz) and peaks are labelled s (singlet), d (doublet), t (triplet), q (quartet), 
dd (doublet of doublets) or m (multiplet). Relevant atoms on molecular structures are labelled 
with numbers to better identify them for analysis. When required, a distinction is made 
between protons attached to the same carbon that have different chemical shifts. Also, where 
there is more than 1 carbon or hydrogen environment on a peak, this is noted and the number 
of protons from each environment is shown (e.g. 2x H-3/7 means 2 of the protons on carbons 
3 and 7, but not all)  
In some cases, carbons and protons are referred to by their functional group (e.g. C=O refers 
to the carbon peak for the carbonyl group, and ArC refers to a carbon in an aromatic 
environment) or by their adjacent numbered carbons (e.g. C-1=C refers to the carbon 
connected to carbon 1 via an alkene bond, with the carbon in question in bold/underlined 
text) Mass spectra were recorded using a Bruker MicroTOF which used electrospray (ES) 





4.2 Precursor molecules syntheses 
 





A solution of 2-cyanoacetic acid (1.2759 g, 15 mmol) and cyclopropanecarbaldehyde (1.1208 
mL, 15 mmol) in absolute ethanol (150 mL) was treated portion-wise with piperidine (0.1482 
mL, 1.5 mmol) and stirred at 60 degrees for 3 hrs. The resulting mixture was cooled to room 
temperature and dried under vacuum to give a wet white solid. The crude product was 
purified by flash chromatography (98:2 DCM: Methanol) to give a white powdery solid 
(2.0565 g, 46%). TOFMS m/z (ESI+): 138.0546 (M+H+, C7H8NO2 requires 138.0550), 
160.0371 (M+Na+, C7H7NNaO2 requires 160.0369);  1H NMR (400 MHz, CD3OD): 7.12 (d, 
1H, H-1, J 11.4), 2.06 (m, 1H, H-2), 1.34 (m, 2H, H-4), 1.03 (m, 2H, H-3); 13C NMR (400 
MHz, CD3OD): 169.0 (C-1), 163.0 (C=O), 114.4 (CN), 105.5 (C-1=C), 15.4 (C-2), 10.2 (C-3 
and C-4) 
 





A solution of 2-cyanoacetic acid (1.2759 g, 15 mmol) and cyclohexanecarbaldehyde (1.8175 
mL, 15 mmol) in absolute ethanol (150 mL) was treated portion-wise with piperidine (0.1482 
mL, 1.5 mmol) and stirred at 60 degrees for 3 hrs. The resulting mixture was cooled to room 
temperature and dried under vacuum to give a wet white solid. The crude product was 



















(0.9619 g, 36%). TOFMS m/z (ESI+): 202.0838 (M+Na+, C10H13NNaO2 requires 202.0838); 
1H NMR (400 MHz, CD3OD): 7.51 (d, 1H, H-1, J 10.3), 2.68 (m, 1H, H-2), 1.83 (m, 2H, H-
4a and H-6a), 1.76 (m, 3H, H-3a, H-7a, H-5a), 1.38 (m, 5H, H-4b, H-5b, H-6b, H-3b, H-7b); 13C 
NMR (400 MHz, CD3OD): 167.1 (C-1), 162.8 (C=O), 113.6 (CN), 108.0 (C-1=C), 41.2 (C-3 
and C-7), 30.7 (C-2), 25.1 (1x C-4/5/6), 24.7 (2x C-4/5/6) 





A solution of 2-cyanoacetic acid (1.2759 g, 15 mmol) and benzaldehyde (1.5303 mL, 15 
mmol) in absolute ethanol (150 mL) was treated portion-wise with piperidine (0.1482 mL, 
1.5 mmol) and stirred at 60 degrees for 3 hrs. The resulting mixture was cooled to room 
temperature and dried under vacuum to give a wet white solid. The crude product was 
purified by flash chromatography (98:2 DCM: Methanol) to give a white solid (0.6902 g, 
27%). TOFMS m/z (ESI+): 174.0544 (M+H+, C10H8NO2 requires 174.0550), 196.0361 
(M+Na+, C10H7NNaO2 requires 196.0374); 1H NMR (400 MHz, CD3OD): 8.34 (s, 1H, H-1), 
8.04, (d, 2H, H-3 and H-7, J 7.6), 7.59, (m, 3H, H-4, H-5, H-6); 13C NMR (400 MHz, 
CD3OD): 163.5 (C-1), 154.5 (C=O), 132.8 (C-2), 131.8 (C-3 and C-7), 130.5 (C-4 and C-6), 



























Compound 3 (0.0866 g, 0.5 mmol), HOBt.H2O (0.0811 g, 0.6 mmol) and EDC.HCl (0.1150 
g, 0.6 mmol) were dissolved in DCM:DMF (2 mL, 10:1 v/v) at 0οC and stirred for 10 minutes 
under inert atmosphere. Then, benzylamine (0.0601 mL, 0.55 mmol) and DIPEA (0.2298 
mL, 1.32 mmol) were added and the reaction continued at 0oC for 30 minutes. The mixture 
was stirred at room temperature for a further 24 hrs. The solution was then dried under 
vacuum to give a yellow oil, which was purified by flash chromatography (10:4 Petrol: 
EtOAc) to give pure product as a white solid. TOFMS m/z (ESI+): 263.1173 (M+H+, 
C17H15N2O requires 263.1179), 285.1006 (M+Na+, C17H14N2NaO requires 285.0998); 1H 
NMR (400 MHz, CD3OD): 8.23 (s, 1H, H-1), 8.00 (d, 2H, H-3 and H-7, J 7.5), 7.56 (m, 3H, 
H-4, H-5, H-6), 7.36 (m, 4H, Ar-H), 7.28 (m, 1H, Ar-H), 4.55 (s, 2H, H-2); 13C NMR (400 
MHz, CD3OD): 151.6 (C=O), 132.3 (C-1), 130.1 (ArC), 128.9 (ArC) 128.1 (ArC), 127.2 







Compound 1 (0.0686 g, 0.5 mmol), HOBt.H2O (0.0811 g, 0.6 mmol) and EDC.HCl (0.1150 
g, 0.6 mmol) were dissolved in DCM:DMF (2 mL, 10:1 v/v) at 0οC and stirred for 10 minutes 
under inert atmosphere. Then, benzylamine (0.0601 mL, 0.55 mmol) and DIPEA (0.2298 




















was stirred at room temperature for a further 24 hrs. The solution was then dried under 
vacuum to give a yellow oil, which was purified by flash chromatography (10:4 Petrol: 
EtOAc) to give pure product as a white flaky solid (17.3 mg, 15%). TOFMS m/z (ESI+): 
227.1172 (M+H+, C14H15N2O requires 227.1179), 249.1007 (M+Na+, C14H14N2NaO requires 
249.0998); 1H NMR (400 MHz, CD3OD): 7.31 (m, 5H, Ar-H), 6.95 (d, 1H, H-1, J 11.2), 4.47 
(s, 2H, H-5), 2.05 (m, 1H, H-2), 1.30 (m, 2H, H-4), 0.97 (m, 2H, H-3); 13C NMR (400MHz, 
CD3OD): 163.4 (C-1), 160.1 (C=O), 136.8 (ArC), 126.6 (ArC), 125.6 (ArC), 125.3 (ArC), 
113.1 (CN), 105.6 (C-1=C), 41.6 (C-5), 13.6 (C-2), 8.1 (C-3 and C-4) 
 






Compound 1 (0.0686 g, 0.5 mmol), HOBt.H2O (0.0811 g, 0.6 mmol) and EDC.HCl (0.1150 
g, 0.6 mmol) were dissolved in DCM:DMF (2 mL, 10:1 v/v) at 0οC and stirred for 10 minutes 
under inert atmosphere. Then, 1-boc-piperazine (0.1025 g, 0.55 mmol) and DIPEA (0.2298 
mL, 1.32 mmol) were added and the reaction continued at 0oC for 30 minutes. The mixture 
was stirred at room temperature for a further 24 hrs. The solution was then dried under 
vacuum to give a yellow oil, which was purified by flash chromatography (10:4 Petrol: 
EtOAc) to give pure product as a white solid (27.1 mg, 18%). TOFMS m/z (ESI+): 328.1641 
(M+Na+, C16H23N3NaO3 requires 328.1632), 323.2078 (M+NH4+, C16H27N4O3 requires 
323.2078); 1H NMR (400 MHz, CD3OD): 6.59 (d, 1H, H-1, J 11.1), 3.63 (m, 4H, 4x H-
5/6/7/8), 3.51 (m, 4H, 4x H-5/6/7/8), 2.05 (m, 1H, H-2), 1.49 (s, 9H, t-Bu), 1.35 (m, 2H, H-
4), 0.95 (m, 2H, H-3) 13C NMR (400MHz, CD3OD): 163.3 (C=O), 161.7 (C-1), 158.8 (C-9), 
113.2 (CN), 104.8 (C-1=C), 78.9 (C-(CH3)3), 78.8 (C-5, C-6, C-7, C-8), 25.7 (C-(CH3)3) 13.5 























Compound 1 (0.0686 g, 0.5 mmol), EDC.HCl (0.1150 g, 0.6 mmol) and HOBt.H2O (0.0811 
g, 0.6 mmol) were dissolved in DCM:DMF (2 mL, 10:1 v/v) at 0οC and stirred for 10 minutes 
under inert atmosphere. Then, 3-(trifluoromethyl)aniline (0.0687 mL, 0.55 mmol) and 
DIPEA (0.2298 mL, 1.32 mmol) were added and the reaction continued at 0oC for 30 
minutes. The mixture was stirred at room temperature for a further 24 hrs. The solution was 
then dried under vacuum to give a yellow oil, which was purified by flash chromatography 
(1:2 Petrol: EtOAc) to give pure product as a yellow solid (34 mg, 24%). TOFMS m/z (ESI+): 
303.0715 (M+Na+, C14H11N2F3NaO requires 303.0721); 1H NMR (400 MHz, CD3OD): 8.04 
(s, 1H, Ar-H), 7.85 (m, 1H, Ar-H), 7.55 (t, 1H, Ar-H, J 8.1), 7.45 (m, 1H, Ar-H), 7.08 (d, 1H, 
H-1, J 11.1), 2.11 (m, 1H, H-2), 1.36 (m, 2H, H-4), 1.05 (m, 2H, H-3); 13C NMR (400 MHz, 
CD3OD): 166.7 (C=O), 160.5 (C-1), 138.7 (ArC), 129.3 (ArC), 129.2 (ArC), 123.9 (ArC), 
120.7 (ArC), 117.2 (ArC), 114.4 (CN), 108.0 (C-1=C), 15.4 (C-2), 9.9 (C-3 and C-4) 
 





Compound 2 (0.0896 g, 0.5 mmol), HOBt.H2O (0.0811 g, 0.6 mmol) and EDC.HCl (0.1150 
g, 0.6 mmol) were dissolved in DCM:DMF (2 mL, 10:1 v/v) at 0οC and stirred for 10 minutes 
under inert atmosphere. Then, 2-morpholino ethan-1-amine (0.0722 mL, 0.55 mmol) and 
DIPEA (0.2298 mL, 1.32 mmol) were added and the reaction continued at 0oC for 30 
minutes. The mixture was stirred at room temperature for a further 24 hrs. The solution was 






























(1:2 Petrol: EtOAc) to give pure product as a yellow oil (20.1 mg, 14%). TOFMS m/z (ESI+): 
292.2025 (M+H+, C16H26N3O2 requires 292.2020), 314.1846 (M+Na+, C16H25N3NaO2 
requires 314.1839); 1H NMR (400 MHz, CD3OD): 7.35 (d, 1H, H-1, J 10.2), 3.72 (t, 4H, H-
11 and H-13, J 4.7), 3.45 (t, 2H, H-8, J 6.6), 2.66 (m, 1H, H-2), 2.56 (t, 2H, H-9, J 6.6), 2.52 
(m, 4H, H-10 and H-12), 1.83 (m, 2H, H-4a and H-6a), 1.76 (m, 3H,  H-3a, H-7a, H-5a), 1.38 
(m, 5H, H-4b, H-5b, H-6b, H-3b, H-7b); 13C NMR (400  MHz, CD3OD): 161.4 (C-1), 159.9 
(C=O), 112.4 (CN), 108.1 (C-1=C), 64.9 (C-11 and C-13), 55.3 (C-10 and C-12), 51.7 (C-9), 







Compound 2 (0.0896 g, 0.5 mmol), EDC.HCl (0.1150 g, 0.6 mmol) and HOBt.H2O (0.0811 
g, 0.6 mmol) were dissolved in DCM:DMF (2 mL, 10:1 v/v) at 0οC and stirred for 10 minutes 
under inert atmosphere. Then, benzylamine (0.0601 mL, 0.55 mmol) and DIPEA (0.2298 
mL, 1.32 mmol) were added and the reaction continued at 0oC for 30 minutes. The mixture 
was stirred at room temperature for a further 24 hrs. The solution was then dried under 
vacuum to give a yellow oil, which was purified by flash chromatography (10:4 Petrol: 
EtOAc) to give pure product as a yellow oil (45 mg, 34%). TOFMS m/z (ESI+): 269.1637 
(M+H+, C17H21N2O requires 269.1648), 291.1473 (M+Na+, C17H20N2NaO requires 
291.1468); 1H NMR (400 MHz, CD3OD): 7.33 (m, 6H, Ar-H + H-1), 3.37 (s, 2H, H-8), 2.67 
(m, 1H, H-2), 1.75 (m, 5H, H-3a, H-4a, H-7a, H-5a, H-6a), 1.32 (m, 5H, H-3b, H-4b, H-5b, H-
6b, H-7b); 13C NMR (400 MHz, CD3OD): 163.0 (C-1), 153.7 (C=O) 138.2 (ArC), 128.6 
(ArC), 128.4 (ArC), 128.2 (ArC), 127.2 (ArC), 126.9 (CN), 110.2 (C-1=C) 43.3 (C-8), 41.2 




















Compound 3 (0.0866 g, 0.5 mmol) and HATU (0.2281 g, 0.6 mmol) were dissolved in 
DCM:DMF (2 mL, 10:1 v/v) at 0οC and stirred for 10 minutes under inert atmosphere. Then, 
3-(trifluoromethyl) aniline (0.0687 mL, 0.55 mmol) and DIPEA (0.2298 mL, 1.32 mmol) 
were added and the reaction continued at 0oC for 30 minutes. The mixture was stirred at room 
temperature for a further 24 hrs, before being diluted with water and washed with EtOAc. 
The organic layer was dried using anhydrous sodium sulphate and the solvent was evaporated 
under vacuum to give an orange/brown wet solid, which was purified by flash 
chromatography (1:5 Petrol: EtOAc) to give pure product as a yellow wet solid (75 mg, 
47%). TOFMS m/z (ESI+): 339.0714 (M+Na+, C17H11F3N2NaO requires 339.0716); 1H NMR 
(400 MHz, CD3OD): 8.32 (s, 1H, Ar-H), 8.12 (s, 1H, H-1), 8.06 (d, 2H, H-3 and H-7, J 7.5), 
7.58 (m, 4H (Under impurities), H-4, H-5, H-6 and 1x Ar-H), 7.23 (t, 1H, Ar-H, J 7.9), 6.88 
(d, 1H, Ar-H, J 7.9); 13C NMR (400 MHz, CD3OD): 157.2 (C=O), 156.4 (C-1), 130.3 (ArC), 







Compound 1 (0.0696 g, 0.5 mmol) and HATU (0.2281 g, 0.6 mmol) were dissolved in 
DCM:DMF (2 mL, 10:1 v/v) at 0οC and stirred for 10 minutes under inert atmosphere. Then, 
cyclohexylamine (0.0631 mL, 0.55 mmol) and DIPEA (0.2298 mL, 1.32 mmol) were added 
and the reaction continued at 0oC for 30 minutes. The mixture was stirred at room 


























The organic layer was dried using anhydrous sodium sulphate and the solvent was evaporated 
under vacuum to give a yellow oil, which was purified by flash chromatography (1:5 Petrol: 
EtOAc) to give pure product as a yellow solid (46 mg, 42%). TOFMS m/z (ESI+): 219.1489 
(M+H+, C13H19N2O requires 219.1492), 241.1314 (M+Na+, C13H18N2NaO requires 
241.1317); 1H NMR (400 MHz, CD3OD): 6.87 (d, 1H, H-1, J 11.1), 3.48 (m, 1H, H-5), 2.05 
(m, 1H, H-2), 1.91 (m, 5H, H-6, H-10 and 1x H-8), 1.79 (m, 5H, H-7, H-8, H-9), 1.34 (m, 
2H, H-4), 0.97 (m, 2H, H-3); 13C NMR (400 MHz, CD3OD): 164.0 (C-1), 161.0 (C=O), 114.8 
(CN), 107.8 (C-1=C), 49.4 (C-5), 32.0 (C-6 and C-10), 31.7 (C-8), 29.4 (C-7 and C-9), 15.1 
(C-2), 9.5 (C-3 and C-4) 
 





Compound 1 (0.0686 g, 0.5 mmol) and HATU (0.2281 g, 0.6 mmol) were dissolved in 
DCM:DMF (2 mL, 10:1 v/v) at 0οC and stirred for 10 minutes under inert atmosphere. Then, 
4-fluoroaniline (0.0521 mL, 0.55 mmol) and DIPEA (0.2298 mL, 1.32 mmol) were added 
and the reaction continued at 0oC for 30 minutes. The mixture was stirred at room 
temperature for a further 24 hrs, before being diluted with water and washed with EtOAc. 
The organic layer was dried using anhydrous sodium sulphate and the solvent was evaporated 
under vacuum to give an orange oil, which was purified by flash chromatography (1:4 Petrol: 
EtOAc) to give pure product as a yellow solid (18 mg, 16%). TOFMS m/z (ESI+): 253.0752 
(M+Na+, C13H11FN2O requires 253.0748); 1H NMR (400 MHz, CD3OD): 7.58 (m, 2H, Ar-
H), 7.07 (m, 3H, 2x Ar-H and H-1), 2.11 (m, 1H, H-2), 1.34 (m, 2H, H-4), 1.03 (m, 2H, H-3); 
13C NMR (400 MHz, CD3OD): 165.2 (C=O), 145.1 (C-1), 123.1 (ArC), 123.0 (ArC), 115.0 
(C-1=C), 114.8 (CN), 15.3 (C-2), 9.8 (C-3 and C-4); 19F NMR (400 MHz, CD3OD): -117.82 



















Compound 1 (0.0686 g, 0.5 mmol) and HATU (0.2281 g, 0.6 mmol) were dissolved in 
DCM:DMF (2 mL, 10:1 v/v) at 0οC and stirred for 10 minutes under inert atmosphere. Then, 
4-methyl piperidine (0.0702 g, 0.55 mmol) and DIPEA (0.2298 mL, 1.32 mmol) were added 
and the reaction continued at 0oC for 30 minutes. The mixture was stirred at room 
temperature for a further 24 hrs, before being diluted with water and washed with EtOAc. 
The organic layer was dried using anhydrous sodium sulphate and the solvent was evaporated 
under vacuum to give an orange oil, which was purified by flash chromatography (1:4 Petrol: 
EtOAc) to give pure product as a yellow oil (20 mg, 18%). TOFMS m/z (ESI+): 219.1484 
(M+H+, C13H19N2O requires 219.1492), 241.1321 (M+Na+, C13H18N2NaO requires 
241.1311); 1H NMR (400 MHz, CD3OD): 6.51 (d, 1H, H-1, J 11.0), 4.49 (m, 1H, 1x H-5/6), 
3.91 (m, 1H, 1x H-5/6), 3.20 (m, 1H, 1x H-5/6), 2.77 (m, 1H, 1x H-5/6), 2.03 (m, 1H under 
ethyl acetate, H-2), 1.78 (m, 1H, 1x H-7/8), 1.74 (m, 1H, 1x H-7/8), 1.70 (m, 1H, 1x H-7/8), 
1.15 (m, 3H, 1x H-7/8 and 2x H-3), 1.00 (m, 3H, H-10), 0.93 (m, 2H, H-3), 0.86 (m, 1H, H-
9); 13C NMR (400 MHz, CD3OD): 171.6 (C=O), 163.7 (C-1), 114.8 (CN), 106.9 (C-1=C), 
42.2 (C-5 and C-6), 34.4 (1x C7/8), 33.4 (1x C-7/8), 30.7 (C-9), 19.5 (C-10), 14.9 (C-2), 13.1 






























Compound 1 (0.0686 g, 0.5 mmol) and HATU (0.2281 g, 0.6 mmol) were dissolved in 
DCM:DMF (2 mL, 10:1 v/v) at 0οC and stirred for 10 minutes under inert atmosphere. Then, 
5-bromo-3-(1,2,3,6-tetrahydropyridin-4-yl)-indole (0.1525 g, 0.55 mmol) and DIPEA (0.2298 
mL, 1.32 mmol) were added and the reaction continued at 0oC for 30 minutes. The mixture 
was stirred at room temperature for a further 24 hrs, before being diluted with water and 
washed with EtOAc. The organic layer was dried using anhydrous sodium sulphate and the 
solvent was evaporated under vacuum to give an orange crude oil, which was purified by 
flash chromatography (1:4 Petrol: EtOAc) to give pure product as a pale-yellow solid (60 mg, 
30%). TOFMS m/z (ESI+): 396.0699 (M+H+, C20H19BrN3O requires 396.0706), 418.0528 
(M+Na+, C20H18BrN3NaO requires 418.0525); 1H NMR (400 MHz, (CD3)2SO): 7.98 (s, 1H, 
H-10), 7.51 (s, 1H, H-13), 7.37 (d, 1H, H-12, J 8.6), 7.24 (dd, 1H, H-11, J 8.6, 1.8), 6.67 (d, 
1H, H-1, J 11.0), 6.15 (m, 1H, H-7), 4.24 (m, 2H, H-6), 4.03 (m, 2H, H-5), 3.74 (t, 2H, H-8, J 
5.8), 1.94 (m, 1H, H-2), 1.19 (m, 2H, H-4), 0.94 (m, 2H, H-3); 13C NMR (400 MHz, 
(CD3)2SO): 164.2 (C=O), 162.2 (C-1), 135.9 (C-10), 130.0 (ArC), 126.6 (C-9), 125.0 (ArC), 
124.4 (ArC), 122.5 (ArC), 117.0 (C-7), 116.1 (CN), 115.5 (ArC), 114.1 (C-10=C), 112.7 (C-





























Compound 1 (0.0686 g, 0.5 mmol) and HATU (0.2281 g, 0.6 mmol) were dissolved in 
DCM:DMF (2 mL, 10:1 v/v) at 0οC and stirred for 10 minutes under inert atmosphere. Then, 
4-methyl piperidine (0.0651 mL, 0.55 mmol) and DIPEA (0.2298 mL, 1.32 mmol) were 
added and the reaction continued at 0oC for 30 minutes. The mixture was stirred at room 
temperature for a further 24 hrs, before being diluted with water and washed with EtOAc. 
The organic layer was dried using anhydrous sodium sulphate and the solvent was evaporated 
under vacuum to give a yellow crude oil, which was purified by flash chromatography (1:4 
Petrol: EtOAc) to give pure product as a yellow oil (68 mg, 55%). TOFMS m/z (ESI+): 
247.0634 (M+H+, C13H12ClN2O requires 247.0633), 269.0453 (M+Na+, C13H11ClN2NaO 
requires 269.0452); 1H NMR (400 MHz, (CD3)2SO): 10.16 (s, 1H, NH), 7.64 (m, 2H, H-5 
and H-6), 7.41 (m, 2H, H-7 and H-8), 7.09 (d, 1H, H-1, J 11.0), 1.95 (m, 1H, H-2), 1.30 (m, 
2H, H-4), 1.02 (m, 2H, H-3); 13C NMR (400 MHz, (CD3)2SO): 165.4 (C=O), 162.4 (C-1) 








Compound 2 (0.0896 g, 0.5 mmol) and HATU (0.2281 g, 0.6 mmol) were dissolved in 
DCM:DMF (2 mL, 10:1 v/v) at 0οC and stirred for 10 minutes under inert atmosphere. Then, 
3-(trifluoromethyl)phenylmethanamine (0.0789 mL, 0.55 mmol) and DIPEA (0.2298 mL, 
1.32 mmol) were added and the reaction continued at 0oC for 30 minutes. The mixture was 
























give an orange oil, which was purified by flash chromatography (1:2 Petrol: EtOAc) to give 
pure product as a yellow oil (105 mg, 62%). TOFMS m/z (ESI+): 359.1344 (M+Na+, 
C18H19F3N2ONa requires 359.1347); 1H NMR (400 MHz, CD3OD): 7.61 (m, 4H, Ar-H), 7.37 
(d, 1H, H-1, J 10.2), 4.54 (s, 2H, H-8), 2.68 (m, 1H, H-2), 1.78 (m, 5H, H-3a, H-4a, H-7a, H-
5a, H-6a), 1.41 (m, 2H, H-5b, 1x H-4/6b), 1.35 (m, 1H, 1x H-4/6b), 1.31 (m, 2H, H-3b and H-
7b); 13C NMR (400 MHz, CD3OD): 163.5 (C-1), 163.3 (C=O), 139.7 (ArC), 137.0 (ArC), 
131.1 (ArC), 129.6 (ArC), 129.1 (CF3), 124.0 (ArC), 123.7 (ArC), 113.9 (CN), 109.6 (C-







Compound 2 (0.0896 g, 0.5 mmol) and HATU (0.2281 g, 0.6 mmol) were dissolved in 
DCM:DMF (2 mL, 10:1 v/v) at 0οC and stirred for 10 minutes under inert atmosphere. Then, 
4-chloroaniline (0.0702 g, 0.55 mmol) and DIPEA (0.2298 mL, 1.32 mmol) were added and 
the reaction continued at 0oC for 30 minutes. The mixture was stirred at room temperature for 
a further 24 hrs. The solution was then dried under vacuum to give a viscous orange oil, 
which was purified by flash chromatography (1:2 Petrol: EtOAc) to give pure product as an 
orange oil (47 mg, 33%). TOFMS m/z (ESI+): 311.0920 (M+Na+, C16H17ClN2NaO requires 
311.0922); 1H NMR (400 MHz, CD3OD): 7.62 (m, 2H, H-8 and H-9), 7.42 (m, 1H, H-1), 
7.36 (m, 2H, H-10 and H-11), 2.72 (m, 1H, H-2), 1.81 (m, 5H, H-3a, H-4a, H-7a, H-5a, H-6a), 
1.41 (m, 1H, H-5b), 1.34 (m, 2H, H-4b and H-6b), 1.31 (m, 1H, H-3/7b), 1.28 (t, 1H, H-3/7b, J 
3.2); 13C NMR (400  MHz, CD3OD): 163.2 (C=O), 160.3 (C-1), 136.5 (ArC), 129.1 (ArC), 
128.5 (ArC), 128.4 (ArC), 122.3 (ArC), 116.1 (CN), 110.6 (C-1=C), 41.4 (1x C-3/7), 37.5 

























Compound 2 (0.0896 g, 0.5 mmol) and HATU (0.2281 g, 0.6 mmol) were dissolved in 
DCM:DMF (2 mL, 10:1 v/v) at 0οC and stirred for 10 minutes under inert atmosphere. Then, 
4-methyl piperidine (0.0651 mL, 0.55 mmol) and DIPEA (0.2298 mL, 1.32 mmol) were 
added and the reaction continued at 0oC for 30 minutes. The mixture was stirred at room 
temperature for a further 24 hrs. The solution was then dried under vacuum to give an orange 
oil, which was purified by flash chromatography (1:2 Petrol: EtOAc) to give pure product as 
a yellow oil (35 mg, 27%). TOFMS m/z (ESI+): 261.1961 (M+H+, C16H25N2O requires 
261.1961), 283.1793 (M+Na+, C16H24N2NaO requires 283.1781) 1H NMR (400 MHz, 
CD3OD): 6.82 (d, 1H, H-1, J 10.0), 4.44 (m, 1H, 1x H-8/9), 3.93 (m, 1H, 1x H-8/9), 3.19 (m, 
1H, 1x H-8/9), 2.81 (m, 1H, 1x H-8/9), 2.63 (m, 1H, H-2), 1.77 (m, 8H, H-10, H-11, H-12, 
H-4a, H-6a and 1x H-3/7a), 1.37 (m, 5H, H-4b, H-6b, H-5 and 1x H-3/7a), 1.17 (m, 2H, H-3b 
and H-7b), 1.00 (d, 3H, Me, J 6.1); 13C NMR (400 MHz, CD3OD): 162.5 (C=O), 161.2 (C-1), 
113.8 (CN), 109.1 (C-1=C), 42.1 (1x C-8/9), 41.2 (1x C-8/9), 39.9 (1x C-10/11), 34.3 (1x C-









Compound 2 (0.0896 g, 0.5 mmol) and HATU (0.2281 g, 0.6 mmol) were dissolved in 
DCM:DMF (2 mL, 10:1 v/v) at 0οC and stirred for 10 minutes under inert atmosphere. Then, 































were added and the reaction continued at 0oC for 30 minutes. The mixture was then stirred at 
room temperature for a further 24 hrs. The solution was then dried under vacuum to give a 
viscous yellow oil, which was purified by flash chromatography (1:2 Petrol: EtOAc) to give 
pure product as an orange oil (52 mg, 29%). TOFMS m/z (ESI+): 352.2400 (M+H+, 
C22H30N3O requires 352.2383), 374.2185 (M+Na+, C22H29N3NaO requires 374.2203); 1H 
NMR (400 MHz, CD3OD): 7.31 (m, 6H, 5x Ar-H and H-1), 3.77 (m, 1H, H-8), 3.53 (m, 2H, 
2x H-11/12), 2.93 (m, 2H, 2x H-11/12), 2.83 (s, 2H, H-13), 2.64 (m, 1H, H-2), 2.10 (m, 1H, 
1x H-9/10), 1.91 (m, 1H, 1x H-9/10), 1.83 (m, 3H, 3x H-4a, H-6a and 1x H-3/7a), 1.75 (m, 
2H, 1x H-3/7a and H-5a), 1.65 (m, 2H, 2x H-9/10), 1.36 (m, 5H, H-3b, H-4b, H-5b, H-6b, H-
7b); 13C NMR (400 MHz, CD3OD): 160.8 (C-1), 159.7 (C=O), 135.6 (ArC), 127.9 (ArC), 
126.5 (ArC), 125.6 (ArC), 112.4 (CN), 108.7 (C-1=C), 60.9 (C-13), 59.1 (1x C-11/12), 58.6 
(1x C-11/12), 50.6 (C-8), 39.7 (1x C-3/7), 36.0 (1x C-3/7), 29.4 (1x C-2 and 1x C-9/10), 29.1 
(1x C-9/10), 23.7 (C-5), 23.3 (C-4 and C-6) 
 




Compound 2 (0.0896 g, 0.5 mmol) and HATU (0.2281 g, 0.6 mmol) were dissolved in 
DCM:DMF (2 mL, 10:1 v/v) at 0οC and stirred for 10 minutes under inert atmosphere. Then, 
pyridin-3-yl methanamine (0.0560 mL, 0.55 mmol) and DIPEA (0.2298 mL, 1.32 mmol) 
were added and the reaction continued at 0oC for 30 minutes. The mixture was stirred at room 
temperature for a further 24 hrs, before being diluted with water and washed with EtOAc. 
The organic layer was dried using anhydrous sodium sulphate and the solvent was evaporated 
under vacuum to give a yellow crude oil, which was purified by flash chromatography (1:4 
Petrol: EtOAc) to give pure product as a white solid (7.1 mg, 5%). TOFMS m/z (ESI+): 
270.1615 (M+H+, C16H20N3O requires 270.1601), 292.1441 (M+Na+, C16H19N3NaO requires 
292.1426); 1H NMR (400 MHz, CD3OD): 8.54 (m, 1H, H-13), 8.46 (dd, 1H, H-12, J 4.9, 
1.6), 7.84 (m, 1H, H-10), 7.43 (dd, 1H, H-11, J 7.9, 4.9), 7.36 (d, 1H, H-1, J 10.2), 4.51 (s, 
2H, H-8), 2.67 (m, 1H, H-2), 1.83 (m, 1H, 1x H-4/6a), 1.75 (m, 4H, 1x H-4/6a, H-3a, H-7a, H-

















163.4 (C=O), 148.2 (C-13), 147.6 (C-12), 136.8 (1x C-9/10), 136.4 (1x C-9/10), 123.9 (C-
11), 113.7 (CN), 109.4 (C-1=C), 41.2 (C-8), 40.8 (C-2), 30.8 (C-3 and C-7) , 25.1 (C-5), 24.7 
(C-4 and C-6) 
4.4 Glutathione NMR tests 
 
Inhibitor in excess: 
L-glutathione reduced (4.6 μmol, 1.41 mg) and a cyanoacrylamide (50 mmol) were made into 
separate solutions in deuterated DMSO-d6. These were then mixed together and a 1H NMR 
was taken every hour for 3-4 hrs. The size of the β-hydrogen integral was calculated by 
setting one of the known peaks on the inhibitor to its known value and comparing to the 
original pure inhibitor spectrum.   
 
1:1 reaction: 
L-glutathione reduced (0.02 mmol, 6.15 mg) and one of the fragment compounds above (0.02 
mmol) were made into separate solutions in deuterated DMSO-d6. These were then mixed 
together and a 1H NMR was taken every hour for 3-4 hrs. The size of the β-hydrogen integral 
was calculated by setting one of the known peaks on its inhibitor to its known value and 
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NMR and Mass spectrometry data 
Characteristic spectroscopic data for each molecule made in this project is listed in this 
section. Full spectra files can be accessed in the research database, with the files 
corresponding to the experiment titles in my lab book. The data has been made available in 
this report as well for ease of access and to show the purest form of each compound because 
each sample has a variety of NMR’s associated with it.   



































































































































































































































































































































Glutathione test data 
The tables below list the integral size data gathered for each numbered compound tested that 
resulted in any inhibition event. This data was used to gather the graphs (like that in Figure 
26) and the rate constants for each reaction by plotting the natural log of the integral against 
time. The first table shows the data for the first experiment which was ran with excess 
inhibitor. The rest were done in 1:1 ratios of inhibitor and glutathione: 
Appendix 21: Compound 12 (excess) 
Hour  Integral size Ln(integrals) 
0 1 0 
1 0.79 -0.235722334 
2 0.81 -0.210721031 
3 0.82 -0.198450939 
24 0.79 -0.235722334 
 
Appendix 22: Compound 16 (1:1) 
Hour Integral size  Ln(integrals) 
0 1 0 
1 0.92 -0.083381609 
2 0.89 -0.116533816 
3 0.85 -0.162518929 
4 0.89 -0.116533816 







Appendix 23: Compound 11 (1:1) 
Hour Integral size Ln(integrals) 
0 1 0 
1 1.1 0.09531018 
2 1.02 0.019802627 
3 0.79 -0.235722334 
4 0.9 -0.105360516 
24 0.9 -0.105360516 
 
Appendix 24: Compound 8 (1:1) 
Hour Integral size Ln(integrals) 
0 1 0 
1 0.66 -0.415515444 
2 0.54 -0.616186139 
3 0.57 -0.562118918 
24 0.59 -0.527632742 
 
Appendix 25: Compound 6 (1:1) 
Hour Integral size Ln(integrals) 
0 1 0 
1 0.68 -0.385662481 
2 0.65 -0.430782916 
3 0.65 -0.430782916 
24 0.64 -0.446287103 
 
